Biallelic variants in FLII cause pediatric cardiomyopathy by disrupting cardiomyocyte cell adhesion and myofibril organization.
Autorzy:
Ruijmbeek CW; Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands. Housley F; Department of Developmental Genetics, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany. Idrees H; Medical Clinic I (Cardiology/Angiology) and Campus Kerckhoff, Justus-Liebig-University Giessen, Giessen, Germany.; Excellence Cluster Cardio-Pulmonary Institute (CPI), Giessen/Bad Nauheim, Germany. HousleyMP; Department of Developmental Genetics, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany. Pestel J; Department of Developmental Genetics, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany. Keller L; Department of Developmental Genetics, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany. Lai JK; Department of Developmental Genetics, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany. der Linde HCV; Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands. Willemsen R; Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands. Piesker J; Scientific Service Group Microscopy, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany. Al-Hassnan ZN; Department of Medical Genetics, and.; Cardiovascular Genetics Program, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia. Almesned A; Prince Sultan Cardiac Center, Buraidah, Saudi Arabia. Dalinghaus M; Department of Pediatric Cardiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands. den Bersselaar LMV; Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands. van Slegtenhorst MA; Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands. Tessadori F; Hubrecht Institute-KNAW and University Medical Center Utrecht, Utrecht, Netherlands. Bakkers J; Hubrecht Institute-KNAW and University Medical Center Utrecht, Utrecht, Netherlands.; Department of Pediatric Cardiology, University Medical Center Utrecht, Utrecht, Netherlands. van Ham TJ; Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands. Stainier DY; Department of Developmental Genetics, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.; Excellence Cluster Cardio-Pulmonary Institute (CPI), Giessen/Bad Nauheim, Germany.; German Centre for Cardiovascular Research (DZHK), RheinMain partner site, Bad Nauheim, Germany. Verhagen JM; Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands. Reischauer S; Department of Developmental Genetics, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.; Medical Clinic I (Cardiology/Angiology) and Campus Kerckhoff, Justus-Liebig-University Giessen, Giessen, Germany.; Excellence Cluster Cardio-Pulmonary Institute (CPI), Giessen/Bad Nauheim, Germany.; German Centre for Cardiovascular Research (DZHK), RheinMain partner site, Bad Nauheim, Germany.
Pokaż więcej
Źródło:
JCI insight [JCI Insight] 2023 Sep 08; Vol. 8 (17). Date of Electronic Publication: 2023 Sep 08.
Broad betacoronavirus neutralization by a stem helix-specific human antibody.
Autorzy:
Pinto D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Sauer MM; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Czudnochowski N; Vir Biotechnology, San Francisco, CA 94158, USA. Low JS; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland. Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. HousleyMP; Vir Biotechnology, San Francisco, CA 94158, USA. Noack J; Vir Biotechnology, San Francisco, CA 94158, USA. Walls AC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Guarino B; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Rosen LE; Vir Biotechnology, San Francisco, CA 94158, USA. di Iulio J; Vir Biotechnology, San Francisco, CA 94158, USA. Jerak J; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland. Kaiser H; Vir Biotechnology, San Francisco, CA 94158, USA. Islam S; Vir Biotechnology, San Francisco, CA 94158, USA. Jaconi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Sprugasci N; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Culap K; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Abdelnabi R; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, 3000 Leuven, Belgium. Foo C; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, 3000 Leuven, Belgium. Coelmont L; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, 3000 Leuven, Belgium. Bartha I; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Bianchi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Silacci-Fregni C; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Bassi J; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Marzi R; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Vetti E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Cassotta A; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland. Ceschi A; Clinical Trial Unit, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.; Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.; Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, 8091 Zurich, Switzerland.; Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland. Ferrari P; Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.; Department of Medicine, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.; Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia. Cippà PE; Department of Medicine, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.; Faculty of Medicine, University of Zurich, 8057 Zurich, Switzerland. Giannini O; Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.; Department of Medicine, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland. Ceruti S; Intensive Care Unit, Clinica Luganese Moncucco, 6900 Lugano, Switzerland. Garzoni C; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland. Riva A; III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, 20157 Milan, Italy. Benigni F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Piccoli L; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Pizzuto MS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Smithey M; Vir Biotechnology, San Francisco, CA 94158, USA. Hong D; Vir Biotechnology, San Francisco, CA 94158, USA. Telenti A; Vir Biotechnology, San Francisco, CA 94158, USA. Lempp FA; Vir Biotechnology, San Francisco, CA 94158, USA. Neyts J; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, 3000 Leuven, Belgium. Havenar-Daughton C; Vir Biotechnology, San Francisco, CA 94158, USA. Lanzavecchia A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Sallusto F; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.; Institute of Microbiology, ETH Zurich, 8093 Zurich, Switzerland. Snell G; Vir Biotechnology, San Francisco, CA 94158, USA. Virgin HW; Vir Biotechnology, San Francisco, CA 94158, USA.; UT Southwestern Medical Center, Dallas, TX 75390, USA.; Washington University School of Medicine, St. Louis, MO 63110, USA. Beltramello M; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2021 Sep 03; Vol. 373 (6559), pp. 1109-1116. Date of Electronic Publication: 2021 Aug 06.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape.
Autorzy:
Starr TN; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Czudnochowski N; Vir Biotechnology, San Francisco, CA, USA. Liu Z; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA. Zatta F; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Park YJ; Department of Biochemistry, University of Washington, Seattle, WA, USA. Addetia A; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Pinto D; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Beltramello M; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Hernandez P; Vir Biotechnology, San Francisco, CA, USA. Greaney AJ; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Genome Sciences, University of Washington, Seattle, WA, USA. Marzi R; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Glass WG; Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Zhang I; Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Tri-Institutional PhD Program in Computational Biology and Medicine, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA. Dingens AS; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA, USA. Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA, USA. Walls AC; Department of Biochemistry, University of Washington, Seattle, WA, USA. Wojcechowskyj JA; Vir Biotechnology, San Francisco, CA, USA. De Marco A; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Rosen LE; Vir Biotechnology, San Francisco, CA, USA. Zhou J; Vir Biotechnology, San Francisco, CA, USA. Montiel-Ruiz M; Vir Biotechnology, San Francisco, CA, USA. Kaiser H; Vir Biotechnology, San Francisco, CA, USA. Dillen JR; Vir Biotechnology, San Francisco, CA, USA. Tucker H; Vir Biotechnology, San Francisco, CA, USA. Bassi J; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Silacci-Fregni C; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. HousleyMP; Vir Biotechnology, San Francisco, CA, USA. di Iulio J; Vir Biotechnology, San Francisco, CA, USA. Lombardo G; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Agostini M; Vir Biotechnology, San Francisco, CA, USA. Sprugasci N; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Culap K; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Jaconi S; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Meury M; Vir Biotechnology, San Francisco, CA, USA. Dellota E Jr; Vir Biotechnology, San Francisco, CA, USA. Abdelnabi R; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium. Foo SC; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium. Cameroni E; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Stumpf S; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA. Croll TI; Cambridge Institute for Medical Research, Department of Haematology, University of Cambridge, Cambridge, UK. Nix JC; Molecular Biology Consortium, Advanced Light Source, Lawrence Berkeley National Laboratory, Berkeley, CA, USA. Havenar-Daughton C; Vir Biotechnology, San Francisco, CA, USA. Piccoli L; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Benigni F; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Neyts J; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium. Telenti A; Vir Biotechnology, San Francisco, CA, USA. Lempp FA; Vir Biotechnology, San Francisco, CA, USA. Pizzuto MS; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Chodera JD; Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hebner CM; Vir Biotechnology, San Francisco, CA, USA. Virgin HW; Vir Biotechnology, San Francisco, CA, USA.; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA. Whelan SPJ; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA. Veesler D; Department of Biochemistry, University of Washington, Seattle, WA, USA. Corti D; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. . Bloom JD; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. .; Department of Genome Sciences, University of Washington, Seattle, WA, USA. .; Howard Hughes Medical Institute, Seattle, WA, USA. . Snell G; Vir Biotechnology, San Francisco, CA, USA. .
Pokaż więcej
Źródło:
Nature [Nature] 2021 Sep; Vol. 597 (7874), pp. 97-102. Date of Electronic Publication: 2021 Jul 14.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
Broad sarbecovirus neutralization by a human monoclonal antibody.
Autorzy:
Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, Paris, France. Czudnochowski N; Vir Biotechnology, San Francisco, CA, USA. Starr TN; Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Marzi R; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Walls AC; Department of Biochemistry, University of Washington, Seattle, WA, USA. Zatta F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA, USA. Jaconi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Di Iulio J; Vir Biotechnology, San Francisco, CA, USA. Wang Z; Department of Biochemistry, University of Washington, Seattle, WA, USA. De Marco A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Zepeda SK; Department of Biochemistry, University of Washington, Seattle, WA, USA. Pinto D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Liu Z; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA. Beltramello M; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Bartha I; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. HousleyMP; Vir Biotechnology, San Francisco, CA, USA. Lempp FA; Vir Biotechnology, San Francisco, CA, USA. Rosen LE; Vir Biotechnology, San Francisco, CA, USA. Dellota E Jr; Vir Biotechnology, San Francisco, CA, USA. Kaiser H; Vir Biotechnology, San Francisco, CA, USA. Montiel-Ruiz M; Vir Biotechnology, San Francisco, CA, USA. Zhou J; Vir Biotechnology, San Francisco, CA, USA. Addetia A; Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Guarino B; Vir Biotechnology, San Francisco, CA, USA. Culap K; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Sprugasci N; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Saliba C; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Vetti E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Giacchetto-Sasselli I; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Fregni CS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Abdelnabi R; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium. Foo SC; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium. Havenar-Daughton C; Vir Biotechnology, San Francisco, CA, USA. Schmid MA; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Benigni F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. Neyts J; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium. Telenti A; Vir Biotechnology, San Francisco, CA, USA. Virgin HW; Vir Biotechnology, San Francisco, CA, USA. Whelan SPJ; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA. Snell G; Vir Biotechnology, San Francisco, CA, USA. Bloom JD; Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Howard Hughes Medical Institute, Seattle, WA, USA. Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. . Veesler D; Department of Biochemistry, University of Washington, Seattle, WA, USA. . Pizzuto MS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. .
Pokaż więcej
Źródło:
Nature [Nature] 2021 Sep; Vol. 597 (7874), pp. 103-108. Date of Electronic Publication: 2021 Jul 19.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
Cavin4b/Murcb Is Required for Skeletal Muscle Development and Function in Zebrafish.
Autorzy:
HousleyMP; Department of Biochemistry and Biophysics, University of California, San Francisco (UCSF), San Francisco, California, United States of America.; Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany. Njaine B; Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany. Ricciardi F; Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany. Stone OA; Department of Biochemistry and Biophysics, University of California, San Francisco (UCSF), San Francisco, California, United States of America.; Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany. Hölper S; Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany. Krüger M; Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany. Kostin S; Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany. Stainier DY; Department of Biochemistry and Biophysics, University of California, San Francisco (UCSF), San Francisco, California, United States of America.; Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
Pokaż więcej
Źródło:
PLoS genetics [PLoS Genet] 2016 Jun 13; Vol. 12 (6), pp. e1006099. Date of Electronic Publication: 2016 Jun 13 (Print Publication: 2016).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins.
Autorzy:
Hart GW; Department of Biological Chemistry, Johns Hopkins University, School of Medicine, 725 North Wolfe Street, Baltimore, Maryland 21205-2185, USA. />HousleyMP Slawson C
Pokaż więcej
Źródło:
Nature [Nature] 2007 Apr 26; Vol. 446 (7139), pp. 1017-22.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Review
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies